A new artificial intelligence (AI)–based tool shows promise for improving surveillance in patients treated with endoscopic eradication therapies for Barrett’s esophagus (BE) related dysplasia and early esophageal adenocarcinoma. BE, is the only known condition that precedes esophageal adenocarcinoma - an aggressive cancer with high mortality rates.

Developed and validated by U.S. researchers, the AI model was over 90% accurate at predicting which patients would experience a recurrence of BE after endoscopic eradication therapy (EET) and detecting when it’s likely to occur.

The findings were published today in Clinical Gastroenterology and Hepatology.

Scientists have created a new “molecular map” uncovering how an important human receptor involved in blood clotting and inflammation works—an advance that could help us design better drugs for conditions such as pulmonary arterial hypertension, cardiovascular disease, and certain cancers.

The study, which was led by an international team including researchers from Trinity College Dublin and published in leading international journal, Nature Communications, used advanced cryo-electron microscopy to capture high-res images of the “thromboxane A₂ receptor ” while it was active and primed to send signals across the membrane to the cell interior. 

This receptor is found on blood platelets and many other cell types, where it helps regulate blood clot formation, blood vessel contraction, and inflammatory responses.